PPD实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments...

Stats
今日成交量	1.87M
平均成交量	1.44M
市值	0.00
EPS	$0.430 ( 2021-10-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.151 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-08	Carlyle Group Inc.	Sell	55 722 733	Common Stock
2021-12-08	H&f Corporate Investors Vii, Ltd.	Sell	157 138	Common Stock
2021-12-08	Johnston David Michael	Buy	33 228	Stock Options (Right to Buy)
2021-12-08	Johnston David Michael	Buy	25 522	Common Stock
2021-12-08	Johnston David Michael	Sell	151 747	Stock Options (Right to Buy)

INSIDER POWER
0.00
Last 98 transactions
Buy: 2 703 151 \| Sell: 89 993 839

音量相关性

長: 0.17 (neutral)

短: 0.34 (neutral)

Signal:(54.867) Neutral

PPD Inc 相关性

10 最正相关
IDLB	0.957
IVAC	0.957
PRAX	0.953
DXJS	0.952
ADAL	0.951
KRMD	0.949
GEEX	0.949
ADMA	0.948
RNEM	0.948
LYTS	0.947

10 最负相关
RIDE	-0.957
MSEX	-0.955
FFIE	-0.954
IMBI	-0.951
VUZI	-0.95
ASLE	-0.949
NKTX	-0.949
DSGN	-0.948
TBLT	-0.947
FWRD	-0.945

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

PPD Inc 相关性 - 货币/商品

0.79
( moderate )

0.41
( neutral )

0.00
( neutral )

0.36
( neutral )

-0.79
( moderate negative )

PPD Inc 财务报表

Annual	2020
营收:	$4.68B
毛利润:	$1.80B (38.42 %)
EPS:	$0.350

FY	2020
营收:	$4.68B
毛利润:	$1.80B (38.42 %)
EPS:	$0.350

FY	2019
营收:	$4.03B
毛利润:	$1.62B (40.24 %)
EPS:	$0.161

FY	2018
营收:	$3.75B
毛利润:	$1.47B (39.32 %)
EPS:	$0.300

Financial Reports:

No articles found.

PPD Inc

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.